Comparing two methods for placing tumor markers in lung cancer treatment
Real-time Guided Stereotactic Radiotherapy in Lung Cancer Using Endovascular Coils for Tumor Marking: Head-to-head Comparison Between Endovascular and Bronchoscopic Fiducial Marker Insertion
This study is testing two different ways to place tiny markers in lung cancer patients to see which method helps doctors target tumors more accurately during treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire Vaudois Academic / other |
| Locations | 1 site (Lausanne, Canton of Vaud) |
| Trial ID | NCT04684186 on ClinicalTrials.gov |
What this trial studies
This study compares endovascular and bronchoscopic methods for inserting fiducial markers in patients with lung cancer. These markers help guide real-time stereotactic radiotherapy using Cyberknife technology, which improves the accuracy of targeting tumors while minimizing damage to surrounding healthy tissue. The study focuses on patients with early-stage or advanced lung cancer who are not suitable for surgery. By evaluating the effectiveness of these two insertion techniques, the research aims to enhance treatment outcomes for lung cancer patients.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 to 85 with early-stage or advanced lung cancer who cannot undergo surgery.
Not a fit: Patients under 18 years old or those unable to provide informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved precision in lung cancer treatment, potentially enhancing survival rates and reducing side effects.
How similar studies have performed: Previous studies have shown promising results with similar fiducial marker placement techniques in improving outcomes for lung cancer treatment.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Lung cancer (primary or secondary, any histological type) * Early stage lung cancer: patients diagnosed with stage I for which operation is contra-indicated, for example because of cardiac or pulmonary comorbidities. * Locally advanced lung cancer stages II - IIIB * Metastatic lung cancer stage IV (palliative care) * 18 y ≤ age ≤ 85 y Exclusion Criteria: * age \<18y * incapacity of judgment * Absence of a signed consent form
Where this trial is running
Lausanne, Canton of Vaud
- Centre Hospitalier Universitaire vaudois - Department of Radiology and Interventional Radiology — Lausanne, Canton of Vaud, Switzerland (Recruiting)
Study contacts
- Study coordinator: Rafael DURAN, MD
- Email: rafael.duran@chuv.ch
- Phone: +41213144444
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.